IDRA.OQ
Latest Trade
1.01USDChange
-0.01(-0.98%)Volume
161,747Today's Range
-
1.0552 Week Range
-
6.11As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 1.02 |
|---|---|
Open | 1.03 |
Volume | 161,747 |
3M AVG Volume | 64.73 |
Today's High | 1.05 |
Today's Low | 1.00 |
52 Week High | 6.11 |
52 Week Low | 1.00 |
Shares Out (MIL) | 42.26 |
Market Cap (MIL) | 46.48 |
Forward P/E | -1.48 |
Dividend (Yield %) | -- |
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial Of Tilsotolimod + Ipilimumab In Anti-PD-1 Refractory Advanced Melanoma
Idera Pharmaceuticals Posts Q4 Loss Per Share $2.11
Idera Pharmaceuticals Reports Third Quarter Financial Results And Provides Corporate Update
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
Industry
Biotechnology & Drugs
Contact Info
505 Eagleview Blvd Ste 212
EXTON, PA
19341-1199
United States
+1.484.3481600
http://www.iderapharma.com/Executive Leadership
james A. Geraghty
Independent Chairman of the Board
Vincent J. Milano
President, Chief Executive Officer, Director
John J. Kirby
Chief Financial Officer, Senior Vice President
Daniel B. Soland
Chief Operating Officer, Senior Vice President
Bryant David Lim
Senior Vice President, General Counsel, Corporate Secretary
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -794.96 |
Return on Equity (TTM) | -250.67 |
* IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA
Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo :
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.